Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMD NASDAQ:MDXG NASDAQ:NYXH NASDAQ:PLSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$13.74+0.6%$14.33$13.14▼$19.85$868.49M1.931.02 million shs1.73 million shsMDXGMiMedx Group$7.16-0.4%$6.44$5.47▼$10.14$1.06B1.791.02 million shs1.30 million shsNYXHNyxoah$7.30-2.1%$7.72$5.55▼$11.87$248.64M1.6143,328 shs60,727 shsPLSEPulse Biosciences$14.75-1.8%$15.81$13.50▼$25.00$992.29M1.6147,924 shs159,304 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode0.00%-6.66%-9.34%-5.70%-24.17%MDXGMiMedx Group0.00%+5.76%+13.92%+13.29%-3.89%NYXHNyxoah0.00%-3.69%-6.05%+19.67%-12.68%PLSEPulse Biosciences0.00%-1.21%-0.31%-14.19%-1.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMDInMode3.1204 of 5 stars3.14.00.00.01.91.71.9MDXGMiMedx Group3.097 of 5 stars3.52.00.00.03.33.30.6NYXHNyxoah2.594 of 5 stars3.54.00.00.01.90.80.6PLSEPulse Biosciences3.9274 of 5 stars3.51.00.04.21.94.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.13Hold$18.0431.31% UpsideMDXGMiMedx Group 3.00Buy$12.0067.60% UpsideNYXHNyxoah 3.00Buy$14.5098.63% UpsidePLSEPulse Biosciences 3.00Buy$22.0049.15% UpsideCurrent Analyst Ratings BreakdownLatest NYXH, PLSE, MDXG, and INMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $12.007/30/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold7/30/2025INMDInModeBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/15/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.007/11/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$15.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$394.82M2.20$1.82 per share7.53$9.94 per share1.38MDXGMiMedx Group$348.88M3.04$0.33 per share21.61$1.46 per share4.90NYXHNyxoah$4.89M50.85N/AN/A$3.60 per share2.03PLSEPulse Biosciences$700K1,417.48N/AN/A$1.87 per share7.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$181.27M$2.475.567.55N/A44.50%18.38%16.35%N/AMDXGMiMedx Group$42.42M$0.2134.1022.38N/A8.84%23.03%17.09%N/ANYXHNyxoah-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)PLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/12/2025 (Estimated)Latest NYXH, PLSE, MDXG, and INMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PLSEPulse Biosciences-$0.26N/AN/AN/AN/AN/A8/5/2025Q2 2025NYXHNyxoah-$0.60N/AN/AN/A$1.33 millionN/A7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 million5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A9.607.86MDXGMiMedx Group0.084.394.13NYXHNyxoah0.223.593.35PLSEPulse BiosciencesN/A15.5815.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%MDXGMiMedx Group79.15%NYXHNyxoahN/APLSEPulse Biosciences76.95%Insider OwnershipCompanyInsider OwnershipINMDInMode6.92%MDXGMiMedx Group1.70%NYXHNyxoah17.11%PLSEPulse Biosciences71.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48063.21 million58.84 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionableNYXH, PLSE, MDXG, and INMD HeadlinesRecent News About These CompaniesPulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth ConferenceAugust 1 at 11:43 AM | finance.yahoo.comPulse Biosciences (NASDAQ:PLSE) Trading 2% Higher - Should You Buy?August 1 at 2:49 AM | marketbeat.comPulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025July 29, 2025 | businesswire.comPulse Biosciences (NASDAQ:PLSE) Stock Price Down 5.9% - Time to Sell?July 11, 2025 | marketbeat.comOppenheimer Initiates Coverage of Pulse Biosciences (PLSE) with Outperform RecommendationJuly 8, 2025 | msn.comPulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.6% - Here's What HappenedJuly 7, 2025 | marketbeat.comOppenheimer Begins Coverage on Pulse Biosciences (NASDAQ:PLSE)July 7, 2025 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Stock Price Down 3.4% - Here's WhyJuly 3, 2025 | marketbeat.comInsider Purchases Worth US$2.70m See Losses As Pulse Biosciences Market Value Drops To US$1.1bJune 17, 2025 | finance.yahoo.comPulse Biosciences, Inc. (NASDAQ:PLSE) CTO Darrin Uecker Sells 15,000 SharesJune 17, 2025 | insidertrades.comPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 23, 2025 | businesswire.comPulse Biosciences, Inc. (NASDAQ:PLSE) insiders have significant skin in the game with 73% ownershipMay 21, 2025 | uk.finance.yahoo.comPulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comPulse Biosciences To Present at the BofA Securities 2025 Health Care ConferenceMay 6, 2025 | businesswire.comPulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual MeetingMay 2, 2025 | finance.yahoo.comPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 25, 2025 | businesswire.comPulse Biosciences (NASDAQ:PLSE) Is In A Strong Position To Grow Its BusinessApril 24, 2025 | finance.yahoo.comPulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025April 24, 2025 | businesswire.comPulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual MeetingApril 23, 2025 | finance.yahoo.comPulse Biosciences: Some Key Questions Remain UnansweredApril 10, 2025 | seekingalpha.comPulse Biosciences: Interesting Product, But No Revenue StreamApril 10, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNYXH, PLSE, MDXG, and INMD Company DescriptionsInMode NASDAQ:INMD$13.74 +0.08 (+0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.85 +0.11 (+0.80%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.MiMedx Group NASDAQ:MDXG$7.16 -0.03 (-0.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.16 0.00 (0.00%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Nyxoah NASDAQ:NYXH$7.30 -0.16 (-2.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.30 0.00 (-0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Pulse Biosciences NASDAQ:PLSE$14.75 -0.27 (-1.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.73 -0.02 (-0.14%) As of 08/1/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
